<DOC>
	<DOCNO>NCT00176488</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin vinorelbine , work different way stop growth tumor cell , either kill cell stop divide . Giving epirubicin together vinorelbine may kill tumor cell . PURPOSE : This phase II trial study well give epirubicin together vinorelbine work treat patient stage II , stage III , stage IV breast cancer .</brief_summary>
	<brief_title>Epirubicin Vinorelbine Treating Patients With Stage II , Stage III , Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess efficacy sequential use epirubicin hydrochloride follow vinorelbine ditartrate patient stage IIB , IIIA , IIIB , IV breast cancer . - Measure biological response regimen sequential tumor biopsy peripheral mononuclear cell patient . - Correlate tumor response change gene expression microtubule-associated protein 4 . OUTLINE : Patients receive epirubicin hydrochloride IV day 1 vinorelbine ditartrate IV 6-10 minute day 3 17 . Patients also receive filgrastim ( G-CSF ) subcutaneously day 4-14 pegfilgrastim IV day 4 . For patient stage IIB ( T3 , N0 ) , IIIA , IIIB disease , treatment repeat every 21 day 5 course absence disease progression unacceptable toxicity . For patient stage IV disease , treatment repeat every 21 day absence disease progression unacceptable toxicity . Blood sample collect baseline course 1 research study . Patients accessible tumor biopsy undergo sequential biopsy core needle biopsy baseline course 1 . Tumor tissue sample use determination p53 status western blot analysis , immunohistochemistry , DNA sequence . Microtubule-associated protein 4 , p53 , p21/WAF1 expression analyze western blotting . After completion study treatment , patient follow 1 month . PROJECTED ACCRUAL : A total 46 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIB ( T3 , N0 ) , IIIA , IIIB , IV breast carcinoma Original tumor must available analysis p53 status Measurable disease , define lesion accurately measure ≥ 1 dimension long diameter ≥ 20 mm use conventional technique OR ≥ 10 mm spiral CT scan Stage IIIB disease assess clinical exam ( monitor skin change well tumor size ) No visceral crisis ( lymphangitic pulmonary spread , liver marrow replacement sufficient cause significant organ dysfunction ) No untreated CNS metastases Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Life expectancy ≥ 8 week Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Bilirubin normal AST ≤ 3 time normal ( ≤ 5 time normal liver metastasis present ) Creatinine ≤ 1.5 mg/dL Ejection fraction ≥ low limit normal MUGA scan ECG Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No malignancy except adequately treat basal cell squamous cell skin cancer situ cervical cancer No preexist disease ( i.e. , cardiac , pulmonary , neurologic , disease ) investigator judge clinically significant No active infectious process , severe malnutrition , intractable emesis PRIOR CONCURRENT THERAPY : Recovered prior therapy At least 3 week since prior radiotherapy At least 3 week since prior chemotherapy Maximum prior doxorubicin hydrochloride dose must ≤ 300 mg/m² OR equivalent anthracycline ( epirubicin hydrochloride ) dose must ≤ 540 mg/m² OR calculate total anthracycline dose must ≤ 540 mg/m² ( determine 1.8 time total doxorubicin hydrochloride dose plus epirubicin hydrochloride dose ) No prior chemotherapy metastatic disease Prior adjuvant chemotherapy , radiotherapy , and/or hormonal therapy breast cancer allow No concurrent radiotherapy except brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>